Why Your Medicare Premium Just Went Up (and What You Can Do About It)

Medical care costs rose 3.4% year-over-year and Medicare costs (Part B premiums and IRMAA surcharges) increased in 2026. Beneficiaries can lower outlays by changing plans during open enrollment (Oct 15–Dec 7; MA changes Jan 1–Mar 31), reducing MAGI (e.g., qualified charitable distributions, above-the-line deductions) to avoid IRMAA, or appealing IRMAA after life‑altering income events such as divorce, a spouse's death, or job loss.

Analysis

Payers and intermediaries are the primary second‑order beneficiaries: plan shopping and IRMAA sensitivity shift negotiating leverage toward lower‑cost Medicare Advantage products and brokers who guide beneficiaries through MAGI optimization. Expect incremental enrollment flows into plans that can demonstrate lower net out‑of‑pocket exposure; even a 1–2pp market‑share swing in a regional MA plan can move EBITDA by high single digits within 12 months because medical loss ratios are tight.

Tax planning and RMD sequencing become an earnings lever for wealth managers and tax‑software vendors: tools that convert RMDs into QCDs or front‑load above‑the‑line deductions will see elevated demand around year‑end and the first quarter. Firms that monetize one‑time planning events (Q4 outreach programs, advisor‑driven IRA strategies) can capture recurring AUM/fee uplifts, turning a seasonal spike into sticky revenue if executed well over 2–4 quarters.

Regulatory and timing risks center on enrollment windows and appeals throughput: a backlog or CMS guidance tightening IRMAA appeal acceptance would compress the “easy” cost savings retirees seek and re‑accelerate complaints to Congress, increasing political risk for insurers' networks and pricing models. Monitor CMS communications and Social Security processing times—an operational slowdown is a near‑term catalyst that would favor larger incumbents with scale to absorb churn.

Technology is the asymmetric trade: AI vendors that reduce adjudication and shopping friction produce cost savings that insurers could share with members to win enrollment. NVDA is the clearest lever here (GPU capacity + enterprise AI stacks); Intel is less differentiated in this niche today, so NVDA gets the disproportionate upside if payers accelerate AI projects over the next 6–18 months.

Key Decisions for Investors

• Long HUM (Humana) 3–9 months — rationale: highest Medicare Advantage exposure and most to gain from modest MA share gains. Target +12–18% vs 10% downside; set 8% stop‑loss and take profits in tranches if enrollment metrics show Q4 MA inflows.
• Pair trade: Long UNH (UnitedHealth) / Short CNC (Centene) 3–6 months — UNH benefits from scale in administration and care platforms while CNC is more exposed to regional MA/Medicaid plan churn. Aim for 1.5:1 reward:risk; unwind if spread tightens <5% or on reversal in CMS guidance.
• Long NVDA via a 6–12 month call spread (buy ATM, sell 20–25% OTM) — to capture accelerated AI adoption for claims adjudication and member analytics. Risk defined to premium; upside asymmetric if payers announce platform rollouts or partnerships in next 6–12 months.
• Long INTU (Intuit) 3–6 months — trade for elevated tax‑planning demand (Q4 RMD optimization and MAGI management) that should boost TurboTax/Tax Advisor workflows and subscription take rates. Target +10% with a 7% stop‑loss; monitor RMD seasonal flows and advisor share gains as catalysts.